Search

Introduction and Purpose Urinary tract infections (UTIs) are a prevalent health issue caused primarily by uropathogenic Escherichia coli (UPEC) and other pathogens, affecting millions annually. These infections encompass lower (cystitis) and upper (pyelonephritis) tract manifestations, presenting with symptoms ranging from dysuria to severe complications like sepsis. Traditional antibiotic treatments, while effective, are increasingly challenged by resistance and adverse effects, necessitating exploration of alternative therapies. Cranberry-derived compounds, particularly proanthocyanidins (PACs), are known for their ability to inhibit bacterial adhesion to uroepithelial cells, a critical step in UTI pathogenesis. Clinical studies suggest that cranberry products may reduce UTI incidence, especially in vulnerable populations such as women and catheterized patients. Probiotics, specifically lactobacilli, contribute to urogenital health by competing with uropathogens for epithelial cell binding sites and producing antimicrobial substances. Emerging research highlights the potential synergistic benefits of combining cranberry extracts with probiotics in UTI prevention strategies. Material and Methods This review is based on articles from the PubMed database, covering the years 2004-2023, using keywords: urinary tract infections, cranberry, probiotics, E. Coli, antibiotics Conclusions Cranberry products and probiotics offer promising non-antibiotic approaches for UTI prevention, targeting fundamental aspects of bacterial pathogenesis. While preliminary studies indicate promising outcomes, rigorous clinical trials are essential to validate these combinations and optimize therapeutic protocols. Further research is warranted to identify specific bioactive compounds within cranberries, standardize probiotic formulations, and establish comprehensive guidelines for their clinical use in UTI management.

Introduction and Purpose Migraine is a widespread neurological disorder characterized by severe, pulsating headaches often accompanied by nausea, vomiting, and hypersensitivity to light and sound. Although its exact cause is still under investigation, recent studies suggest that vitamin D deficiency may play a role in migraine occurrence and severity. Vitamin D, known primarily for its role in bone health, also affects the nervous and immune systems, and may influence inflammatory processes involved in migraine pathogenesis. This literature review aims to explore the relationship between vitamin D supplementation and the frequency and intensity of migraines, and whether supplementation could support migraine treatment. Material and Methods A comprehensive literature review was conducted using the PubMed database, focusing on articles published until the end of 2023. The search included the keywords: "vitamin D," "migraine," "headache," and "supplementation" in various combinations. Relevant studies were selected based on criteria such as monitoring vitamin D levels and the use of supplementation as an intervention in migraine patients. Results The results of the review suggest that vitamin D deficiency may be associated with an increased frequency of migraines. Supplementation with vitamin D was linked to a reduction in both the frequency and severity of migraines. While not all studies were consistent, the majority indicated that supplementation had a positive impact, particularly in individuals with vitamin D deficiency. Conclusions The findings suggest that vitamin D deficiency could be a risk factor for migraines, and that supplementation with vitamin D may help reduce the severity and frequency of migraine attacks. Although further research is required to establish optimal dosages and treatment protocols, vitamin D supplementation shows promise as a supportive therapy in migraine management.

Introduction IgG4-related disease (IgG4-RD) is a progressive and potentially life-threatening condition characterized by immune system activation and tissue fibrosis, affecting various organs such as the pancreas, kidneys, and lungs. Initially recognized in 2003, it often presents as mass-like lesions, which can mimic tumors. Despite advancements in understanding its pathology, epidemiological data are limited, and many patients remain undiagnosed due to unfamiliarity with the disease. Aim of the study The aim of this article wast to summarize the latest knowledge on the diagnosis and clinical manifestations of IgG4-related disease. Materiał and methods This review is based on articles from the PubMed and Google Scholar databases, covering the years 2007-2024, using the keywords: IgG4-related disease; autoimmune pancreatitis; retroperitoneal fibrosis; classification criteria. Results The disease's complex pathogenesis involves B and T cell activity, with genetic and environmental factors contributing. While effective treatments, like B cell depletion, exist, the disease's broad clinical manifestations and multi-organ involvement require a multidisciplinary approach for proper diagnosis and management. Conclusion Diagnosing IgG4-RD is challenging due to its varied symptoms, often mimicking other diseases. Key findings include high IgG4 levels and specific histopathological features. Further research is needed to understand its genetic factors, pathogenesis, and epidemiology.

Introduction and Purpose The gut microbiome is crucial to infant health and development. For premature infants, microbiome development differs from full-term babies, posing long-term health risks. Factors such as delivery method, feeding, antibiotic treatment, and neonatal intensive care unit (NICU) environment significantly influence the microbiome of premature infants. Probiotics, especially Bifidobacterium strains, show promise in enhancing health and reducing risks of necrotizing enterocolitis (NEC) and late-onset sepsis (LOS). Material and Methods This review is based on articles from the PubMed database, covering the years 2004-2023, using keywords: gut microbiome, premature infants, probiotic, microbiome development, and neonatal intensive care unit. Results Current research indicates probiotics, particularly Bifidobacterium strains, positively impact the gut microbiome of premature infants, improving immunity and metabolism, and providing protection against NEC and LOS. Multi-strain probiotic preparations combining Bifidobacterium and Lactobacilaceae strains appear promising, but further research is needed to fully understand their effects. Addressing food intolerance (FI) in premature infants is another potential application of microbiome-focused therapies. Conclusions While probiotics show promise in improving the microbiome of preterm infants, comprehensive research on single and multi-strain probiotics and their specific mechanisms of action is needed. Controversies persist regarding the safety, FDA regulation, and selection of specific probiotics and formulations. There is no consensus on the optimal timing for introducing probiotics. Further research is required to optimize probiotic selection and determine the best benefits. Enhanced standardization and oversight are essential to ensure safe and effective use of probiotics in neonatal healthcare.